Quarterly report pursuant to Section 13 or 15(d)

DEVELOPMENT AWARDS (Details Narrative)

v3.21.2
DEVELOPMENT AWARDS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended 45 Months Ended
Oct. 31, 2021
May 31, 2019
Mar. 31, 2019
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2019
Jun. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Sep. 30, 2021
Jan. 26, 2018
Entity Listings [Line Items]                              
Revenue       $ 97,323   $ 1,230,621     $ 881,705 $ 3,279,026          
Additional paid in capital, fair value of warrant issued           472,409       472,409          
CFF Warrant [Member]                              
Entity Listings [Line Items]                              
Warrant exercisable price per share       $ 13.20         $ 13.20         $ 13.20  
Cystic Fibrosis Foundation [Member]                              
Entity Listings [Line Items]                              
Payments for royalty   $ 2,700,000                          
Collaboration and License Agreement [Member]                              
Entity Listings [Line Items]                              
Revenue from related parties, recorded as deferred revenue             $ 27,000,000                
Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member]                              
Entity Listings [Line Items]                              
Upfront payment, received from related party     $ 27,000,000                        
Consideration receivable on milestone payments     $ 173,000,000                        
Royalty term description     The “Royalty Term” means the period beginning on the date of the first commercial sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party’s insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days’ notice.                        
Contract with customer, liability, current     $ 27,000,000                        
Revenue from related parties, recorded as deferred revenue     27,000,000                        
Royalty payable     $ 27,000,000                        
Cystic Fibrosis Program Related Investment Agreement [Member] | Phase 2b Clinical Trial [Member]                              
Entity Listings [Line Items]                              
Royalty payable   2,700,000                          
Payments for royalty   $ 27,000,000                          
Proceeds from investments on achieving milestones                   22,500,000          
Loans Payable               $ 2,500,000              
Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]                              
Entity Listings [Line Items]                              
Gain Contingency, Unrecorded Amount                             $ 25,000,000
Investment Agreement [Member] | 2018 CFF Award [Member]                              
Entity Listings [Line Items]                              
Revenue       $ 97,323   $ 1,230,621     $ 881,705 $ 3,279,026          
Investment Agreement [Member] | CFF Warrant [Member]                              
Entity Listings [Line Items]                              
Warrant to purchase of common stock       1,000,000         1,000,000         1,000,000  
Warrants expiration term                     Jan. 26, 2025        
Investment Agreement [Member] | CFF Warrant [Member] | Immediately Exercisable Warrants [Member]                              
Entity Listings [Line Items]                              
Warrant to purchase of common stock       500,000         500,000         500,000  
Investment Agreement [Member] | CFF Warrant [Member] | Warrants Exercisable On Completion Of Final Milestone [Member]                              
Entity Listings [Line Items]                              
Warrant to purchase of common stock       500,000         500,000         500,000  
Investment Agreements [Member]                              
Entity Listings [Line Items]                              
Revenue         $ 0     $ 0 $ 0   $ 5,000,000 $ 5,000,000 $ 12,500,000 $ 22,500,000  
Contract asset                 2,500,000   $ 1,618,000        
Investment Agreements [Member] | Subsequent Event [Member]                              
Entity Listings [Line Items]                              
Revenue $ 2,500,000                            
Investment Agreements [Member] | Cystic Fibrosis Foundation Warrants [Member]                              
Entity Listings [Line Items]                              
Revenue                 25,000,000            
Additional paid in capital, fair value of warrant issued                 6,215,225            
Revenue to be recognized       $ 18,784,775         $ 18,784,775         $ 18,784,775